NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates

János Tomcsányi, Erzsébet Nagy, Miklós Somlói, Judit Moldvay, Attila Bezzegh, Béla Bózsik, J. Strausz

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Pleural effusion is not pathognomic and distinguishing between transudates and exudates often presents a diagnostic dilemma. The purpose of our study was to examine whether the inclusion of pleural fluid brain natriuretic peptide (BNP) measurement into the analysis improves the diagnostic accuracy of pleural effusion. Methods: The pleural effusion of 14 patients with CHF (group A) and 14 subjects with different pleural pathology (group B) were analyzed. Samples of pleural fluid and serum were obtained from all patients on admission and biochemical analysis, bacterial and fungal culture, acid-fast bacilli smear and culture and cytology were performed on the pleural fluid. In vitro quantitative determination of N-terminal pro-Brain natriuretic peptide (NT-proBNP) in serum and pleural fluid were performed by electrochemiluminescence immunoassay proBNP method on an Elecsys 2010 (Roche) analyzer. Results: The median NT-proBNP levels in groups A and B were 6295 pg/ml and 276 pg/ml, respectively: (P=0.0001). There was no overlap between the two groups. While the Light's criteria had a sensitivity of 93% and specificity of 43% for transudates, the pleural fluid NT-proBNP level accurately differentiated between the two groups. Conclusions: The pleural NT-proBNP levels were elevated in all patients who had transudate. Therefore if the NT-proBNP levels of pleural effusion are within the normal range, transudate resulting from congestive heart failure can be ruled out. Our results suggest that the inclusion of pleural fluid NT-proBNP measurement in the routine diagnostic panel would enhance discrimination among the different causes of pleural effusions.

Original languageEnglish
Pages (from-to)753-756
Number of pages4
JournalEuropean Journal of Heart Failure
Volume6
Issue number6
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Brain Natriuretic Peptide
Exudates and Transudates
Pleural Effusion
Patient Admission
Serum
Immunoassay
Bacillus
Cell Biology
Reference Values
Heart Failure
Pathology
Sensitivity and Specificity
Acids

Keywords

  • Brain natriuretic peptide
  • Congestive heart failure
  • Pleural effusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates. / Tomcsányi, János; Nagy, Erzsébet; Somlói, Miklós; Moldvay, Judit; Bezzegh, Attila; Bózsik, Béla; Strausz, J.

In: European Journal of Heart Failure, Vol. 6, No. 6, 10.2004, p. 753-756.

Research output: Contribution to journalArticle

Tomcsányi, János ; Nagy, Erzsébet ; Somlói, Miklós ; Moldvay, Judit ; Bezzegh, Attila ; Bózsik, Béla ; Strausz, J. / NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates. In: European Journal of Heart Failure. 2004 ; Vol. 6, No. 6. pp. 753-756.
@article{9bb9d88fb585409ca9f0110fe7b0bc64,
title = "NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates",
abstract = "Background: Pleural effusion is not pathognomic and distinguishing between transudates and exudates often presents a diagnostic dilemma. The purpose of our study was to examine whether the inclusion of pleural fluid brain natriuretic peptide (BNP) measurement into the analysis improves the diagnostic accuracy of pleural effusion. Methods: The pleural effusion of 14 patients with CHF (group A) and 14 subjects with different pleural pathology (group B) were analyzed. Samples of pleural fluid and serum were obtained from all patients on admission and biochemical analysis, bacterial and fungal culture, acid-fast bacilli smear and culture and cytology were performed on the pleural fluid. In vitro quantitative determination of N-terminal pro-Brain natriuretic peptide (NT-proBNP) in serum and pleural fluid were performed by electrochemiluminescence immunoassay proBNP method on an Elecsys 2010 (Roche) analyzer. Results: The median NT-proBNP levels in groups A and B were 6295 pg/ml and 276 pg/ml, respectively: (P=0.0001). There was no overlap between the two groups. While the Light's criteria had a sensitivity of 93{\%} and specificity of 43{\%} for transudates, the pleural fluid NT-proBNP level accurately differentiated between the two groups. Conclusions: The pleural NT-proBNP levels were elevated in all patients who had transudate. Therefore if the NT-proBNP levels of pleural effusion are within the normal range, transudate resulting from congestive heart failure can be ruled out. Our results suggest that the inclusion of pleural fluid NT-proBNP measurement in the routine diagnostic panel would enhance discrimination among the different causes of pleural effusions.",
keywords = "Brain natriuretic peptide, Congestive heart failure, Pleural effusion",
author = "J{\'a}nos Tomcs{\'a}nyi and Erzs{\'e}bet Nagy and Mikl{\'o}s Soml{\'o}i and Judit Moldvay and Attila Bezzegh and B{\'e}la B{\'o}zsik and J. Strausz",
year = "2004",
month = "10",
doi = "10.1016/j.ejheart.2003.11.017",
language = "English",
volume = "6",
pages = "753--756",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - NT-brain natriuretic peptide levels in pleural fluid distinguish between pleural transudates and exudates

AU - Tomcsányi, János

AU - Nagy, Erzsébet

AU - Somlói, Miklós

AU - Moldvay, Judit

AU - Bezzegh, Attila

AU - Bózsik, Béla

AU - Strausz, J.

PY - 2004/10

Y1 - 2004/10

N2 - Background: Pleural effusion is not pathognomic and distinguishing between transudates and exudates often presents a diagnostic dilemma. The purpose of our study was to examine whether the inclusion of pleural fluid brain natriuretic peptide (BNP) measurement into the analysis improves the diagnostic accuracy of pleural effusion. Methods: The pleural effusion of 14 patients with CHF (group A) and 14 subjects with different pleural pathology (group B) were analyzed. Samples of pleural fluid and serum were obtained from all patients on admission and biochemical analysis, bacterial and fungal culture, acid-fast bacilli smear and culture and cytology were performed on the pleural fluid. In vitro quantitative determination of N-terminal pro-Brain natriuretic peptide (NT-proBNP) in serum and pleural fluid were performed by electrochemiluminescence immunoassay proBNP method on an Elecsys 2010 (Roche) analyzer. Results: The median NT-proBNP levels in groups A and B were 6295 pg/ml and 276 pg/ml, respectively: (P=0.0001). There was no overlap between the two groups. While the Light's criteria had a sensitivity of 93% and specificity of 43% for transudates, the pleural fluid NT-proBNP level accurately differentiated between the two groups. Conclusions: The pleural NT-proBNP levels were elevated in all patients who had transudate. Therefore if the NT-proBNP levels of pleural effusion are within the normal range, transudate resulting from congestive heart failure can be ruled out. Our results suggest that the inclusion of pleural fluid NT-proBNP measurement in the routine diagnostic panel would enhance discrimination among the different causes of pleural effusions.

AB - Background: Pleural effusion is not pathognomic and distinguishing between transudates and exudates often presents a diagnostic dilemma. The purpose of our study was to examine whether the inclusion of pleural fluid brain natriuretic peptide (BNP) measurement into the analysis improves the diagnostic accuracy of pleural effusion. Methods: The pleural effusion of 14 patients with CHF (group A) and 14 subjects with different pleural pathology (group B) were analyzed. Samples of pleural fluid and serum were obtained from all patients on admission and biochemical analysis, bacterial and fungal culture, acid-fast bacilli smear and culture and cytology were performed on the pleural fluid. In vitro quantitative determination of N-terminal pro-Brain natriuretic peptide (NT-proBNP) in serum and pleural fluid were performed by electrochemiluminescence immunoassay proBNP method on an Elecsys 2010 (Roche) analyzer. Results: The median NT-proBNP levels in groups A and B were 6295 pg/ml and 276 pg/ml, respectively: (P=0.0001). There was no overlap between the two groups. While the Light's criteria had a sensitivity of 93% and specificity of 43% for transudates, the pleural fluid NT-proBNP level accurately differentiated between the two groups. Conclusions: The pleural NT-proBNP levels were elevated in all patients who had transudate. Therefore if the NT-proBNP levels of pleural effusion are within the normal range, transudate resulting from congestive heart failure can be ruled out. Our results suggest that the inclusion of pleural fluid NT-proBNP measurement in the routine diagnostic panel would enhance discrimination among the different causes of pleural effusions.

KW - Brain natriuretic peptide

KW - Congestive heart failure

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=7944235639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944235639&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2003.11.017

DO - 10.1016/j.ejheart.2003.11.017

M3 - Article

VL - 6

SP - 753

EP - 756

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 6

ER -